Format

Send to

Choose Destination
Presse Med. 2018 Oct;47(10):886-891. doi: 10.1016/j.lpm.2018.10.003. Epub 2018 Oct 25.

[Use and misuse of benzodiazepines in patients with psychiatric disorders].

[Article in French]

Author information

1
Université Bordeaux, Inserm, Bordeaux Population Health Research Center, Pharmacoepidemiology research team, UMR 1219, 33000 Bordeaux, France.
2
Université Bordeaux, Inserm, Bordeaux Population Health Research Center, Pharmacoepidemiology research team, UMR 1219, 33000 Bordeaux, France; Centre hospitalier universitaire de Bordeaux, 33000 Bordeaux, France.
3
Université Bordeaux, Inserm, Bordeaux Population Health Research Center, Pharmacoepidemiology research team, UMR 1219, 33000 Bordeaux, France; Centre hospitalier Charles-Perrens, 33000 Bordeaux, France.
4
Université Bordeaux, Inserm, Bordeaux Population Health Research Center, Pharmacoepidemiology research team, UMR 1219, 33000 Bordeaux, France; Centre hospitalier Charles-Perrens, 33000 Bordeaux, France. Electronic address: mtournier@ch-perrens.fr.

Abstract

The psychiatric patients are not only particularly exposed to benzodiazepines; they may also be more vulnerable to their side effects than general population. Benzodiazepines are frequently misused in psychiatric patients in terms of duration, dose and number of concomitant medications. There is no evidence that benzodiazepines are effective against most psychiatric disorders, including depression and suicidal risk. Several studies have shown associations between benzodiazepine use and depression worsening, increased disinhibition, suicide risk, anxiety, aggression, and even mortality in patients with psychiatric disorders. Despite the common use of benzodiazepine drugs by clinicians, large and methodologically sound studies are lacking to document the patterns of benzodiazepine use in populations with psychiatric disorders and their specific risks in these patients. It is not known whether it is legitimate to apply the good practice recommendations for benzodiazepines in patients with severe psychiatric disorders.

PMID:
30454581
DOI:
10.1016/j.lpm.2018.10.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center